Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD
Show Description +
Why do some clinical trials end with drug approval while others—even those with what appear to be robust, reliable, and encouraging data—end without regulator support? In this episode of Clinical Minute: Retina, Ramin Tadayoni, MD, PhD, invites Peter Kaiser, MD, to share his insights on dynamics surrounding clinical trials in retina. Which disconnects between researchers and regulators exist? Which real-world studies are unable to translate to real-world practice? And how does study design underpin the success or failure of a drug submitted for consideration with regulatory bodies?
Posted: 8/19/2022
Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD
Why do some clinical trials end with drug approval while others—even those with what appear to be robust, reliable, and encouraging data—end without regulator support? In this episode of Clinical Minute: Retina, Ramin Tadayoni, MD, PhD, invites Peter Kaiser, MD, to share his insights on dynamics surrounding clinical trials in retina. Which disconnects between researchers and regulators exist? Which real-world studies are unable to translate to real-world practice? And how does study design underpin the success or failure of a drug submitted for consideration with regulatory bodies?
Posted: 8/19/2022
Please log in to leave a comment.